BioNTech (BNTX) to Release Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($1.38) per share and revenue of $161.26 million for the quarter.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $115.31 on Monday. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The business has a fifty day simple moving average of $107.05 and a 200 day simple moving average of $106.36. The firm has a market cap of $27.72 billion, a price-to-earnings ratio of -33.91 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BNTX shares. JPMorgan Chase & Co. cut their price objective on BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a report on Thursday, May 22nd. Morgan Stanley increased their price objective on BioNTech from $132.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 10th. The Goldman Sachs Group started coverage on BioNTech in a report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price objective for the company. Wall Street Zen upgraded BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, June 7th. Finally, Citigroup reiterated a “buy” rating and set a $140.00 price objective (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.58.

Hedge Funds Weigh In On BioNTech

An institutional investor recently raised its position in BioNTech stock. Royal Bank of Canada grew its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 95.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,177 shares of the company’s stock after purchasing an additional 3,514 shares during the quarter. Royal Bank of Canada’s holdings in BioNTech were worth $653,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.